Mashup Score: 3
American College of CardiologyVupanorsen, an antisense oligonucleotide targeting angiopoietin-like 3 (ANGPTL3), reduced non-high-density lipoprotein (non-HDL) cholesterol by up to 28% in patients who were already taking statins, according to findings from the TRANSLATE-TIMI 70 trial presented April 3 at ACC.22 and simultaneously published in Circulation. Researchers also noted significant reductions in other lipid...
-
123456
Read the full article here